Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects

Clinical and Experimental Allergy

Volumn 45, Issue 5, 2015, Pages 974-981

  Couroux, P ^a,e   Patel, D ^a,f   Armstrong, K ^b   Larche M ^c   Hafner, R P ^d  

^a Cetero Research   (Canada)

^b Adiga Life Sciences   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CIRCASSIA LTD   (United Kingdom)

^e Inflamax Research   (Canada)

^f Topstone Research   (Canada)

Author keywords

Allergic rhinitis; Allergic rhinoconjunctivitis; Cat allergy; Fel d 1; Immune tolerance; Immunotherapy; Persistence; SPIREs; T cell epitopes

Indexed keywords

ALLERGEN; EPITOPE; FEL D 1 PEPTIDE; IMMUNOMODULATING AGENT; PLACEBO; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; FEL D 1 PROTEIN, FELIS DOMESTICUS; GLYCOPROTEIN; PEPTIDE;

ADULT; AGED; ALLERGY; ARTICLE; CAT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; TREATMENT DURATION; ADOLESCENT; ADVERSE EFFECTS; ANIMAL; CHEMISTRY; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; MIDDLE AGED; RHINITIS, ALLERGIC; SYNTHESIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANIMALS; CATS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; PEPTIDES; RHINITIS, ALLERGIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927775059     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12488     Document Type: Article

References (19)

1. Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007; 120:1139-45.
2. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005; 116:377-83.
3. Morris DO. Human allergy to environmental pet danders: a public health perspective. Vet Dermatol 2010; 21:441-9.
4. Worm M, Lee HH, Kleine-Tebbe J et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127:89-97.
5. Larché M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11:569-76.
6. Kiel MA, Röder E, Gerth van Wijk RG, Al MJ, Hop WCJ, Rutten-van Mölken MPMH. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013; 132:353-60.
7. Durham SR, Walker SM, Varga E et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
8. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-25.
9. Madonini E, Agostinis F, Barra R et al. Long-term and preventative effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003; 16:73-9.
10. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007; 117:965-9.
11. Jacobsen L et al. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clinical and Translational Allergy 2012; 2:8.
12. Patel D, Couroux P, Hickey P et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013; 131:103-9.e7.
13. Chapman MD, Wood RA. The role and remediation of animal allergens in allergic diseases. J Allergy Clin Immunol 2001; 107(3 Suppl.):S414-21.
14. Day JH, Horak F, Briscoe MP et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006; 6:31-59.
15. Salapatek AM, Patel P, Chan K, Talwar N, von Weikersthal-Drachenberg KF, Amersdorffer J. An environmental exposure chamber -specific rhinoconjunctivitis quality of life questionnaire: the symptoms of seasonal allergic rhinitis correlate with the quality of life of patients with ragweed allergy in the chamber. Allergy 2007; 62(Suppl. 83):118-9.
16. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:860-7.
17. Patel D, Bernstein DL, Plunkett G et al. Tolerability and efficacy of sublingual immunotherapy in cat allergic subjects studied in an environmental exposure chamber. Ann Allergy Asthma Immunol 2011; 107:A105.
18. Berkowitz RB, Braker S, Lutz C et al. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:327-33.
19. Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs 2013; 22:1347-57.